Literature DB >> 16394087

Topographic molecular profile of pheochromocytomas: role of somatic down-regulation of mismatch repair.

Alfredo Blanes1, Juan J Sanchez-Carrillo, Salvador J Diaz-Cano.   

Abstract

CONTEXT AND
OBJECTIVE: Despite extensive molecular investigation of adrenal pheochromocytomas, no information is available on their molecular and mismatch repair (MMR) profiles by topographic compartments. DESIGN AND
SETTING: Microdissected samples from the peripheral and internal zones of 143 pheochromocytomas from a referral hospital (95 sporadic and 48 associated with multiple endocrine neoplasia type 2A) were selected for loss of heterozygosity and single nucleotide polymorphism analyses. Five polymorphic DNA regions from TP53, RB1, WT1, and NF1 were systematically studied by PCR-denaturing gradient gel electrophoresis. PATIENTS, OUTCOME MEASURES, AND
INTERVENTIONS: Pheochromocytomas were classified as malignant (16 sporadic tumors with distant metastases), locally invasive (30 sporadic tumors showing retroperitoneal infiltration only), and benign (all remaining tumors). Statistical differences were evaluated using Fisher's exact test. MMR was assessed by MLH1/MSH2 sequencing and immunostaining in pheochromocytomas with two or more abnormal microsatellites. No interventions were performed in this study.
RESULTS: Loss of heterozygosity/single nucleotide polymorphism involved TP53 in 40 of 134 informative cases (29.9%), RB1 in 22 of 106 informative cases (20.8%), WT1 in 32 of 120 informative cases (26.7%), and NF1 in 32 of 80 informative cases (40.0%). More genetic abnormalities involving the peripheral compartment were revealed in 34 pheochromocytomas (23.8%): 12 of 16 malignant, 10 of 30 locally invasive, and 12 of 97 benign. Multiple and coexistent genetic abnormalities characterized malignant pheochromocytomas (P < 0.001), whereas locally invasive pheochromocytomas showed a significantly higher incidence of NF1 alterations (P < 0.001). No mutations were identified in MLH1/MSH2, but MMR proteins significantly decreased in peripheral compartments.
CONCLUSIONS: Multiple microsatellite alterations and topographic intratumor heterogeneity characterize malignant pheochromocytomas, suggesting a multistep tumorigenesis through somatic topographic down-regulation of MMR proteins. Locally invasive pheochromocytomas reveal topographic heterogeneity and single-locus microsatellite alterations, especially involving NF1.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16394087     DOI: 10.1210/jc.2005-1645

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  5 in total

Review 1.  Tumor heterogeneity: mechanisms and bases for a reliable application of molecular marker design.

Authors:  Salvador J Diaz-Cano
Journal:  Int J Mol Sci       Date:  2012-02-13       Impact factor: 6.208

2.  Profiling of somatic mutations in phaeochromocytoma and paraganglioma by targeted next generation sequencing analysis.

Authors:  Andrea Luchetti; Diana Walsh; Fay Rodger; Graeme Clark; Tom Martin; Richard Irving; Mario Sanna; Masahiro Yao; Mercedes Robledo; Hartmut P H Neumann; Emma R Woodward; Farida Latif; Stephen Abbs; Howard Martin; Eamonn R Maher
Journal:  Int J Endocrinol       Date:  2015-03-25       Impact factor: 3.257

Review 3.  Pathological bases for a robust application of cancer molecular classification.

Authors:  Salvador J Diaz-Cano
Journal:  Int J Mol Sci       Date:  2015-04-17       Impact factor: 5.923

4.  Mutational Profile and Potential Molecular Therapeutic Targets of Pheochromocytoma.

Authors:  Xiaosen Ma; Chao Ling; Meng Zhao; Fen Wang; Yunying Cui; Jin Wen; Zhigang Ji; Caili Zhang; Shi Chen; Anli Tong; Yuxiu Li
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-28       Impact factor: 6.055

Review 5.  Clinical implications of intratumor heterogeneity: challenges and opportunities.

Authors:  Santiago Ramón Y Cajal; Marta Sesé; Claudia Capdevila; Trond Aasen; Leticia De Mattos-Arruda; Salvador J Diaz-Cano; Javier Hernández-Losa; Josep Castellví
Journal:  J Mol Med (Berl)       Date:  2020-01-22       Impact factor: 4.599

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.